The radiation oncology market size is projected to reach US$ 23,620.56 million by 2031 from US$ 8,924.44 million in 2023. The market is expected to register a CAGR of 13.0% in 2023–2031. Technological advancements in radiation oncology are likely to bring key trends in the market in the coming years.
Governments and private entities are investing in healthcare infrastructure, including radiation therapy centers, to enhance service quality and availability. Thus, the radiation oncology market is driven by initiatives to support developments in radiation oncology for better and effective patient outcomes, along with the increasing prevalence of cancer. Moreover, companies in the radiation oncology market engage in product launches, product approvals, partnerships, mergers and acquisitions, which are expected to create ample opportunities in the market in the coming years.
Radiation oncology is one of the fastest-developing cancer treatment modalities. Technological advancements and increasing awareness among large populations are among the major factors contributing to the radiation oncology market growth. North America dominates the radiation oncology market, and Asia Pacific is expected to register the highest CAGR during the forecast period. Market growth in Asia Pacific is attributed to the presence of developing economies that hold ample growth opportunities. Cancer has quickly become a public health concern in India. Approximately 1.39 million cancer cases were reported in the country in 2020. The disease was also ranked among the world's leading causes of death in 2020, accounting for approximately 10 million deaths. To combat cancer more successfully, the Government of India has implemented several initiatives that focus on investing resources in building adequate infrastructure for cancer care as well as in implementing mass-scale programs for prevention, control, and screening of common cancer types.
Cancer is one of the common health conditions significantly impacting societies worldwide. According to the World Health Organization (WHO), it is the leading cause of death across the world; it was the cause of 20 million new cancer cases and 9.7 million deaths in 2022. The number of new cancer cases is expected to reach ~35 million new cancer cases by 2050. As per the WHO 2024 report, lung cancer is the most common cancer cause of mortality globally, followed by colorectal cancer, liver cancer, breast cancer, and stomach cancer, which are responsible for 18.7%, 9.3%, 7.8%, 6.9%, and 6.8% of the total cancer related deaths, respectively. The incidences of the top 10 cancer types are mentioned in the table below:
Lung
2 480 675
Breast
2 296 840
Colorectum
1 926 425
Prostate
1 467 854
Stomach
968 784
Liver
866 136
Thyroid
821 214
Cervix Uteri
662 301
Bladder
614 298
NHL
553 389
Source: Global Cancer Observatory
The increasing incidence of cancer results in a huge demand for effective treatment options. Radiotherapy is one of the continuously evolving treatment options with effective outcomes for cancer patients. The method of intervention utilizes high doses of radiation such as X-rays and gamma rays to kill cancer cells. Radiation therapy is mainly prescribed in patients with the early stages of cancer, while it can be used at any point in the treatment. Various types of external beam radiotherapy are used for the treatment of different cancer types. For instance, brachytherapy is used for the treatment of breast cancer, cervix cancer, eye cancer, prostate cancer, and head & neck cancer. Further, systemic radiation therapy, also known as radioactive iodine therapy, is used for the treatment of thyroid cancer. Thus, the increasing prevalence of cancer and the evolution of radiotherapy in oncology bolsters the radiation oncology market growth.
Companies in the radiation oncology market are making continuous efforts in terms of product developments, innovations, launches, and approvals; mergers; acquisitions; and partnerships to contribute to the evolution of radiotherapy. A few of the recent strategic initiatives that took place in the market in recent years are mentioned below.
Therefore, strategic initiatives by market players operating in the radiation oncology market are expected to create ample opportunities for the radiation oncology market in the coming years
Key segments that contributed to the derivation of the radiation oncology analysis are type and application.
The geographic scope of the radiation oncology report is mainly divided into five regions: North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America. North America dominates the radiation oncology market, which can be attributed to the increasing prevalence of cancer along with technological advancement in the region. The US is expected to account for the dominating share of the market in this region. The number of professionals having radiation treatment expertise is also on the rise in the country, which can be attributed to the accessibility of a developed healthcare infrastructure. As per the American Society of Clinical Oncology, approximately two-thirds of cancer patients globally are estimated to receive radiation therapy as a part of their treatment. In 2022, over 1 million cancer patients in the US received radiation therapy. The government and healthcare authorities are taking several initiatives to encourage the adoption of radiotherapy. In June 2020, the American Society for Radiation Oncology (ASTRO) introduced new clinical guidelines regarding radiotherapy for nonmetastatic cervical cancer. The new guidelines focus on precisely implementing steps and processes to conduct radiation therapy. Asia Pacific is anticipated to record the highest CAGR during 2023–2031.
The regional trends and factors influencing the Radiation Oncology Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Radiation Oncology Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
Report Attribute | Details |
---|---|
Market size in 2023 | US$ 8,924.44 Million |
Market Size by 2031 | US$ 23,620.56 Million |
Global CAGR (2023 - 2031) | 7.4% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
The Radiation Oncology Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Radiation Oncology Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The radiation oncology market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the market are listed below:
The "Radiation Oncology Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
North America dominated the market in 2023.
The increasing prevalence of cancer and initiatives to support developments in radiation oncology are the pivotal factors fueling the market growth.
The estimated value of the market would be US$ 23,620.56 million by 2031.
Technological advancements are likely to bring attractive trends in the market in the coming years.
Varian Medical Systems Inc, Elekta AB, Accuracy Incorporated, IBA Worldwide (Ion Beam Applications SA), Becton Dickinson & Co, Perspective Therapeutics Inc, Nordion, Mevion Medical Systems, NTP Radioisotopes, and Mallinckrodt Plc are among the key players in the market.
The market is expected to register a CAGR of 13% during 2023–2031.